Skip to the content
Home
About us
Programs
Resource Hub
Membership
Gallery
All Media
Fellowships
Contact Us
X
Home
About us
Programs
Resource Hub
Membership
Gallery
All Media
Fellowships
Contact Us
Menu
Home
About us
Programs
Resource Hub
Membership
Gallery
All Media
Fellowships
Contact Us
Home
About us
Programs
Resource Hub
Membership
Gallery
All Media
Fellowships
Contact Us
Home
About us
Programs
Resource Hub
Membership
Gallery
All Media
Fellowships
Contact Us
Home
About us
Programs
Resource Hub
Membership
Gallery
All Media
Fellowships
Contact Us
Menu
Home
About us
Programs
Resource Hub
Membership
Gallery
All Media
Fellowships
Contact Us
Clinical Trials Centre
Home
Clinical Trials Centre
1. AEGIS-II: CSL112 Associated With Lower Rates of CV Death, MI
2. The DanGer Shock trial: a new dawn but much to uncover
3. Empagliflozin after Acute Myocardial Infarction
4. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
5. Baseline characteristics of patients enrolled in the EMPACT-MI
6. Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI
7. Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial
8. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction
9. REDUCE-AMI: Re-evaluating the role of routine beta-blockade in patients with acute myocardial infarction
10. Prognostic Value of Coronary Angiography–Derived Index of Microcirculatory Resistance in Non–ST-Segment Elevation Myocardial Infarction Patients
11. 3-Year Outcomes of Balloon-Expandable Valves: 20-mm vs Larger Valves (≥23 mm)
12. Clinical Outcomes of Transradial vs Nontransradial Aortoiliac Endovascular Therapy
13. Association of Baseline Tricuspid Regurgitation With Health Status and Clinical Outcomes After TAVR and Mitral TEER
14. Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients
15. Paclitaxel-coated balloon vs uncoated balloon for Instent-RestenosisAGENT-IDE
16. ESC 2024: SELECT trial provides promising results for obesity-related HFpEF treatment
17. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial
18. One-month ticagrelor monotherapy after PCI in acute coronary syndromes: Principal results from the double-blind, placebo-controlled Ultimate DAPT trial
19. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction
20. Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease
21. Invasive Treatment Strategy for Older Patients with Myocardial Infarction
22. Asundexian versus Apixaban in Patients with Atrial Fibrillation
23. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
24. CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
25. QCA versus IVUS to guide DES-implantationGUIDE-DES
26. Microaxial Flow Pump in Infarct-Related Cardiogenic Shock - DanGer Shock
27. Third Nordic Aortic Valve Intervention - NOTION-3
28. DanGer Shock: Impella CP Improves Survival After STEMI With Cardiogenic Shock
29. Optical Coherence Tomography-Guided Coronary Intervention in Patients With Complex Lesions - OCCUPI
30. RECOVER IV Impella Trial Halted in the Wake of DanGer Shock
31. Randomized Evaluation of Decreased Usage of Beta-Blockers After Acute Myocardial Infarction - REDUCE-AMI
32. Transcatheter Repair versus Mitral-Valve Surgery for Secondary Mitral Regurgitation
33. Continuation versus Interruption of Oral Anticoagulation during TAVI
34. PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation
